Comments
Analysts expect the proposed merger of Sun Pharmaceutical Industries and Ranbaxy Laboratories to get green signal from the Competition Commission of India in the next few days. But they expect the watchdog may clear the deal, but will ask the companies to make some changes in the original deal. On April 6, Sun Pharma had announced it would buy Ranbaxy from Daiichi Sankyo in an all-share deal pegged at $4 billion.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.